Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biomed Pharmacother ; 178: 117270, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39126773

ABSTRACT

The blood supply in the retina ensures photoreceptor function and maintains regular vision. Leber's hereditary optic neuropathy (LHON), caused by the mitochondrial DNA mutations that deteriorate complex I activity, is characterized by progressive vision loss. Although some reports indicated retinal vasculature abnormalities as one of the comorbidities in LHON, the paracrine influence of LHON-affected retinal ganglion cells (RGCs) on vascular endothelial cell physiology remains unclear. To address this, we established an in vitro model of mitochondrial complex I deficiency using induced pluripotent stem cell-derived RGCs (iPSC-RGCs) treated with a mitochondrial complex I inhibitor rotenone (Rot) to recapitulate LHON pathologies. The secretomes from Rot-treated iPSC-RGCs (Rot-iPSC-RGCs) were collected, and their treatment effect on human umbilical vein endothelial cells (HUVECs) was studied. Rot induced LHON-like characteristics in iPSC-RGCs, including decreased mitochondrial complex I activity and membrane potential, and increased mitochondrial reactive oxygen species (ROS) and apoptosis, leading to mitochondrial dysfunction. When HUVECs were exposed to conditioned media (CM) from Rot-iPSC-RGCs, the angiogenesis of HUVECs was suppressed compared to those treated with CM from control iPSC-RGCs (Ctrl-iPSC-RGCs). Angiogenesis-related proteins were altered in the secretomes from Rot-iPSC-RGC-derived CM, particularly angiopoietin, MMP-9, uPA, collagen XVIII, and VEGF were reduced. Notably, GeneMANIA analysis indicated that VEGFA emerged as the pivotal angiogenesis-related protein among the identified proteins secreted by health iPSC-RGCs but reduced in the secretomes from Rot-iPSC-RGCs. Quantitative real-time PCR and western blots confirmed the reduction of VEGFA at both transcription and translation levels, respectively. Our study reveals that Rot-iPSC-RGCs establish a microenvironment to diminish the angiogenic potential of vascular cells nearby, shedding light on the paracrine regulation of LHON-affected RGCs on retinal vasculature.


Subject(s)
Human Umbilical Vein Endothelial Cells , Induced Pluripotent Stem Cells , Optic Atrophy, Hereditary, Leber , Retinal Ganglion Cells , Humans , Optic Atrophy, Hereditary, Leber/metabolism , Optic Atrophy, Hereditary, Leber/pathology , Optic Atrophy, Hereditary, Leber/genetics , Induced Pluripotent Stem Cells/drug effects , Induced Pluripotent Stem Cells/metabolism , Human Umbilical Vein Endothelial Cells/metabolism , Human Umbilical Vein Endothelial Cells/drug effects , Retinal Ganglion Cells/metabolism , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/pathology , Mitochondria/drug effects , Mitochondria/metabolism , Phenotype , Reactive Oxygen Species/metabolism , Rotenone/pharmacology , Culture Media, Conditioned/pharmacology , Apoptosis/drug effects , Electron Transport Complex I/metabolism , Membrane Potential, Mitochondrial/drug effects , Neovascularization, Pathologic/metabolism , Angiogenesis
2.
Eur J Pharmacol ; 977: 176676, 2024 Aug 15.
Article in English | MEDLINE | ID: mdl-38815787

ABSTRACT

Wogonin, a vital bioactive compound extracted from the medicinal plant, Scutellaria baicalensis, has been wildly used for its potential in mitigating the progression of chronic diseases. Chronic kidney disease (CKD) represents a significant global health challenge due to its high prevalence, morbidity and mortality rates, and associated complications. This study aimed to assess the potential of wogonin in attenuating renal fibrosis and to elucidate the underlying molecular mechanisms using a unilateral ureteral obstruction (UUO) mouse model as a CKD mimic. Male mice, 8 weeks old, underwent orally administrated of either 50 mg/kg/day of wogonin or positive control of 5 mg/kg/day candesartan following UUO surgery. NRK52E cells were exposed to tumor growth factors-beta (TGF-ß) to evaluate the anti-fibrotic effects of wogonin. The results demonstrated that wogonin treatment effectively attenuated TGF-ß-induced fibrosis markers in NRK-52E cells. Additionally, administration of wogonin significantly improved histopathological alterations and downregulated the expression of pro-fibrotic factors (Fibronectin, α-smooth muscle actin, Collagen IV, E-cadherin, and TGF-ß), oxidative stress markers (Catalase, superoxide dismutase 2, NADPH oxidase 4, and thioredoxin reductase 1), inflammatory molecules (Cyclooxygenase-2 and TNF-α), and the infiltration of neutrophils and macrophages in UUO mice. Furthermore, wogonin treatment mitigated endoplasmic reticulum (ER) stress-associated molecular markers (GRP78, GRP94, ATF4, CHOP, and the caspase cascade) and suppressed apoptosis. The findings indicate that wogonin treatment ameliorates key fibrotic aspects of CKD by attenuating ER stress-related apoptosis, inflammation, and oxidative stress, suggesting its potential as a future therapeutic target.


Subject(s)
Apoptosis , Disease Models, Animal , Endoplasmic Reticulum Chaperone BiP , Endoplasmic Reticulum Stress , Fibrosis , Flavanones , Ureteral Obstruction , Animals , Endoplasmic Reticulum Stress/drug effects , Ureteral Obstruction/complications , Ureteral Obstruction/pathology , Ureteral Obstruction/drug therapy , Flavanones/pharmacology , Flavanones/therapeutic use , Apoptosis/drug effects , Male , Mice , Cell Line , Kidney/drug effects , Kidney/pathology , Kidney/metabolism , Inflammation/drug therapy , Inflammation/pathology , Transforming Growth Factor beta/metabolism , Rats , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/pathology , Mice, Inbred C57BL
3.
J Adv Res ; 2024 Mar 27.
Article in English | MEDLINE | ID: mdl-38548265

ABSTRACT

INTRODUCTION: The clinical presentations of dry eye disease (DED) and depression (DEP) often comanifest. However, the robustness and the mechanisms underlying this association were undetermined. OBJECTIVES: To this end, we set up a three-segment study that employed multimodality results (meta-analysis, genome-wide association study [GWAS] and Mendelian randomization [MR]) to elucidate the association, common pathways and causality between DED and DEP. METHODS: A meta-analysis comprising 26 case-control studies was first conducted to confirm the DED-DEP association. Next, we performed a linkage disequilibrium (LD)-adjusted GWAS and targeted phenotype association study (PheWAS) in East Asian TW Biobank (TWB) and European UK Biobank (UKB) populations. Single-nucleotide polymorphisms (SNPs) were further screened for molecular interactions and common pathways at the functional gene level. To further elucidate the activated pathways in DED and DEP, a systemic transcriptome review was conducted on RNA sequencing samples from the Gene Expression Omnibus. Finally, 48 MR experiments were implemented to examine the bidirectional causation between DED and DEP. RESULTS: Our meta-analysis showed that DED patients are associated with an increased DEP prevalence (OR = 1.83), while DEP patients have a concurrent higher risk of DED (OR = 2.34). Notably, cross-disease GWAS analysis revealed that similar genetic architecture (rG = 0.19) and pleiotropic functional genes contributed to phenotypes in both diseases. Through protein-protein interaction and ontology convergence, we summarized the pleiotropic functional genes under the ontology of immune activation, which was further validated by a transcriptome systemic review. Importantly, the inverse variance-weighted (IVW)-MR experiments in both TWB and UKB populations (p value <0.001) supported the bidirectional exposure-outcome causation for DED-to-DEP and DEP-to-DED. Despite stringent LD-corrected instrumental variable re-selection, the bidirectional causation between DED and DEP remained. CONCLUSION: With the multi-modal evidence combined, we consolidated the association and causation between DED and DEP.

4.
J Chin Med Assoc ; 86(8): 740-747, 2023 08 01.
Article in English | MEDLINE | ID: mdl-37399580

ABSTRACT

BACKGROUND: This study aimed to evaluate the impact of end-stage kidney disease (ESKD) on mortality in patients with first-time acute myocardial infarction (AMI). METHODS: This was a retrospective nationwide cohort study. Patients diagnosed with first-time AMI between January 1, 2000, and December 31, 2012, were included. All patients were followed-up until death or December 31, 2012, whichever occurred first. A one-to-one propensity score matching technique was used to match patients with ESKD to those without ESKD of similar sex, age, comorbidities, and coronary intervention (including percutaneous coronary intervention [PCI] and coronary artery bypass grafting [CABG]). Kaplan-Meier cumulative survival curves were constructed to compare AMI patients with and without ESKD. RESULTS: A total of 186 112 patients were enrolled and 8056 patients with ESKD were identified. Propensity score matched 8056 patients without ESKD were included in the comparison. Overall, the 12-year mortality rate was significantly higher in patients with ESKD than in those without ESKD (log-rank p < 0.0001), including the sex, age, and PCI and CABG subgroups. In Cox proportional-hazard regression analysis, ESKD was an independent risk factor for mortality after patients suffered from first-time AMI (hazard ratio, 1.77; 95% CI, 1.70-1.84; p < 0.0001). A forest plot for subgroup analysis revealed that in AMI patients, ESKD had a higher impact on mortality in male; younger age; without comorbidities such as hypertension, diabetes mellitus, peripheral vascular disease, heart failure, cerebrovascular accident, and chronic obstructive pulmonary disease; and receiving PCI and CABG subgroups. CONCLUSION: ESKD significantly increases the mortality risk in patients with first-time AMI, including both sexes, different ages, and whether PCI or CABG was performed. In patients with AMI, ESKD has a high impact on mortality in male, younger age, without comorbidities, and those undergoing PCI and CABG.


Subject(s)
Coronary Artery Disease , Kidney Failure, Chronic , Myocardial Infarction , Percutaneous Coronary Intervention , Female , Humans , Male , Percutaneous Coronary Intervention/methods , Cohort Studies , Retrospective Studies , Treatment Outcome , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy
5.
IEEE J Transl Eng Health Med ; 10: 4901211, 2022.
Article in English | MEDLINE | ID: mdl-36247084

ABSTRACT

OBJECTIVE: Obstructive sleep apnea (OSA) is a respiratory disease associated with autonomic nervous system dysfunction. As a novel method for analyzing OSA depending on heart rate variability, fuzzy approximate entropy of extrema based on multiple moving averages (Emma-fApEn) can effectively assess the sympathetic tension limits, thereby realizing a good performance in the disease severity screening. METHOD: Sixty 6-h electrocardiogram recordings (20 healthy, 16 mild/moderate OSA and 34 severe OSA) from the PhysioNet database were used in this study. The performances of minima of Emma-fApEn (fApEn-minima), maxima of Emma-fApEn (fApEn-maxima) and classic time-frequency domain indices for each recording were assessed by significance analysis, correlation analysis, parameter optimization and OSA screening. RESULTS: fApEn-minima and fApEn-maxima had significant differences between the severe OSA group and the other two groups, while the mean value (Mean) and the ratio of low-frequency power and high-frequency power (LH) could significantly differentiate OSA recordings from healthy recordings. The correlation coefficient between fApEn-minima and apnea-hypopnea index was the highest (|R| = 0.705). Machine learning methods were used to evaluate the performances of the above four indices. Random forest (RF) achieved the highest accuracy of 96.67% in OSA screening and 91.67% in severe OSA screening, with a good balance in both. CONCLUSION: Emma-fApEn may be used as a simple preliminary detection tool to assess the severity of OSA prior to polysomnography analysis.


Subject(s)
Sleep Apnea, Obstructive , Entropy , Heart Rate/physiology , Humans , Polysomnography/methods , Severity of Illness Index , Sleep Apnea, Obstructive/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL